These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27172434)

  • 1. Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.
    Thirumalai A; Cooper LA; Rubinow KB; Amory JK; Lin DW; Wright JL; Marck BT; Matsumoto AM; Page ST
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2937-44. PubMed ID: 27172434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
    Page ST; Lin DW; Mostaghel EA; Marck BT; Wright JL; Wu J; Amory JK; Nelson PS; Matsumoto AM
    J Clin Endocrinol Metab; 2011 Feb; 96(2):430-7. PubMed ID: 21177791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.
    Mostaghel EA; Lin DW; Amory JK; Wright JL; Marck BT; Nelson PS; Matsumoto AM; Bremner WJ; Page ST
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2809-17. PubMed ID: 22659250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent intraprostatic androgen concentrations after medical castration in healthy men.
    Page ST; Lin DW; Mostaghel EA; Hess DL; True LD; Amory JK; Nelson PS; Matsumoto AM; Bremner WJ
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3850-6. PubMed ID: 16882745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
    Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
    Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
    Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response effects of sex hormone concentrations on body composition and adipokines in medically castrated healthy men administered graded doses of testosterone gel.
    Thirumalai A; Rubinow KB; Cooper LA; Amory JK; Marck BT; Matsumoto AM; Page ST
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):59-67. PubMed ID: 28370068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
    Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
    Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate.
    Marchetti B; Poulin R; Plante M; Labrie F
    J Steroid Biochem; 1988 Oct; 31(4A):411-9. PubMed ID: 2845194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
    Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
    Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment.
    Page ST; Kalhorn TF; Bremner WJ; Anawalt BD; Matsumoto AM; Amory JK
    J Androl; 2007; 28(5):734-41. PubMed ID: 17494097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.
    Wright AS; Thomas LN; Douglas RC; Lazier CB; Rittmaster RS
    J Clin Invest; 1996 Dec; 98(11):2558-63. PubMed ID: 8958218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
    Kunelius P; Lukkarinen O; Hannuksela ML; Itkonen O; Tapanainen JS
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1467-72. PubMed ID: 11932266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.